June 17, 2022 (v1)
Publication
Background and objectives: To evaluate the long-term safety and efficacy of tocilizumab (TCZ), a humanized anti-interleukin-6 receptor antibody in myelin oligodendrocyte glycoprotein-IgG-associated disease (MOGAD) and neuromyelitis optica spectrum disorders (NMOSD). Methods: Annualized relapse rate (ARR), Expanded Disability Status Scale score,...
Uploaded on: April 14, 2023